Background

Retinoblastoma (RB) is the most prevalent primary intraocular malignancy, which commonly occurs during infant and childhood.

Objective

Our study aimed to investigate whether microRNA-9 (miR-9) could regulate RB cells and its mechanism.

Methods

qRT-PCR analysis was used to detect the expression of miR-9. In addition, to detect the migration of RB cells, wound healing assay was conducted. Xenograft tumor models in nude mice were also established, in order to assess the effects of miR-9 on tumor growth. qRT-PCR, luciferase reporter assay and western blot analysis were used to detect the target of miR-9.

Results

Initially, the expression level of miR-9 was significantly decreased in the RB tissues and blood samples from patients with RB. qRT-PCR, luciferase reporter assay and western blot analysis were used to confirm that PTEN was the target genes of miR-9 and it was negatively regulated by miR-9. When the expression of miR-9 was up-regulated, the cell viability, proliferation, migration and tumor formation were significantly suppressed. Furthermore, the expression level of PTEN was decreased after transfection of miR-9 mimic. Taken together, these results indicated that miR-9 might suppress the cell viability, proliferation, migration and tumor formation in RB by inhibiting PTEN.

Conclusion

The in vitro and in vivo experiments demonstrated that miR-9 acts as a tumor suppressor function in RB cells and might serve as novel therapeutic targets for the treatment of RB.

中文翻译：

---

MicroRNA-9 通过靶向 PTEN 抑制视网膜母细胞瘤细胞的增殖和进展

背景

视网膜母细胞瘤 (RB) 是最常见的原发性眼内恶性肿瘤，通常发生在婴儿和儿童期。

客观的

我们的研究旨在调查 microRNA-9 (miR-9) 是否可以调节 RB 细胞及其机制。

方法

qRT-PCR分析用于检测miR-9的表达。此外，为了检测RB细胞的迁移，进行了伤口愈合试验。还建立了裸鼠异种移植肿瘤模型，以评估 miR-9 对肿瘤生长的影响。qRT-PCR、荧光素酶报告基因测定和蛋白质印迹分析用于检测miR-9的靶标。

结果

最初，RB 患者的 RB 组织和血液样本中 miR-9 的表达水平显着降低。qRT-PCR、荧光素酶报告基因检测和蛋白质印迹分析用于确认 PTEN 是 miR-9 的靶基因，并且受 miR-9 负调控。当miR-9的表达上调时，细胞活力、增殖、迁移和肿瘤形成受到显着抑制。此外，转染miR-9模拟物后PTEN的表达水平降低。总之，这些结果表明miR-9可能通过抑制PTEN来抑制RB中的细胞活力、增殖、迁移和肿瘤形成。

结论

体外和体内实验表明，miR-9 在 RB 细胞中起肿瘤抑制功能，可能作为治疗 RB 的新治疗靶点。